Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
Agilent Technologies, Inc (A) (Q1FY25) – Agilent Exceeds Q1 Expectations
$240.00
The Chemical and Advanced Materials segment saw a 2% decline, mainly due to a high-teens drop in China related to Lunar New Year timing. Diagnostics and Clinical grew 7%, driven by strong results in the Americas and Europe.
Description
Description
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
Agilent’s Q1 revenue was $1.68 billion, exceeding the top end of guidance despite the strengthening of the U.S. dollar. Gross margin was 54.7%, down from last year, mainly due to mix, currency, and Lunar New Year timing. Operating margins were 25.1%, in line with expectations, despite currency challenges
Agilent in the last 3 months, the stock has given a negative return of (33%). The stock price decreased to $102 as of Apr 22, 2025, from $152.6 as of Jan 22, 2025.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/agilent-technologies-equity-report-q4-24/
